Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of PP 1420 in Healthy Subjects
NCT02221765Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Aug 2014
- Primary completion
- May 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PP 1420 in obesity (2 arms), sponsored by Imperial College London. Primary endpoint: Safety and tolerability. Started Aug 2014; status: terminated.
02
Drugs
PP 1420
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02221765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02221765.